These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35633567)

  • 1. Conjugation of Cetuximab - Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines.
    Puspitasari D; Wanandi SI; Sadikin M
    Asian Pac J Cancer Prev; 2022 May; 23(5):1803-1812. PubMed ID: 35633567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines.
    Gurdal H; Tuglu MM; Bostanabad SY; Dalkiliç B
    Int J Oncol; 2019 Apr; 54(4):1345-1356. PubMed ID: 30720056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer.
    Colombo M; Rizzuto MA; Pacini C; Pandolfi L; Bonizzi A; Truffi M; Monieri M; Catrambone F; Giustra M; Garbujo S; Fiandra L; Corsi F; Prosperi D; Mazzucchelli S
    Bioconjug Chem; 2018 Nov; 29(11):3817-3832. PubMed ID: 30350574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    McKnight BN; Kim S; Boerner JL; Viola NT
    Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis.
    Xu W; Song C; Wang X; Li Y; Bai X; Liang X; Wu J; Liu J
    Aging (Albany NY); 2021 Jan; 13(1):228-240. PubMed ID: 33472170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
    Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
    Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
    Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
    Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.
    Cheung A; Chenoweth AM; Johansson A; Laddach R; Guppy N; Trendell J; Esapa B; Mavousian A; Navarro-Llinas B; Haider S; Romero-Clavijo P; Hoffmann RM; Andriollo P; Rahman KM; Jackson P; Tsoka S; Irshad S; Roxanis I; Grigoriadis A; Thurston DE; Lord CJ; Tutt ANJ; Karagiannis SN
    Clin Cancer Res; 2024 Aug; 30(15):3298-3315. PubMed ID: 38772416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
    El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
    Mol Carcinog; 2017 May; 56(5):1383-1394. PubMed ID: 27864890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
    El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
    Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen.
    Nagaya T; Sato K; Harada T; Nakamura Y; Choyke PL; Kobayashi H
    PLoS One; 2015; 10(8):e0136829. PubMed ID: 26313651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
    El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
    PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
    Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro.
    Abrahams B; Gerber A; Hiss DC
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.
    Wang JG; Yu J; Hu JL; Yang WL; Ren H; Ding D; Zhang L; Liu XP
    Cell Signal; 2015 Jul; 27(7):1315-24. PubMed ID: 25817575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
    Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging.
    Wang K; Wang K; Li W; Huang T; Li R; Wang D; Shen B; Chen X
    Acta Radiol; 2009 Dec; 50(10):1095-103. PubMed ID: 19922304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.